Tardive Dyskinesia (TD) Treatment Drugs Market Report 2022: Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts to 2029 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Tardive Dyskinesia (TD) Treatment Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 to 2029" report has been added to ResearchAndMarkets.com's offering.

Tardive dyskinesia (TD) is a rare neurological disorder due to long term use of antipsychotic medications which act on dopamine receptors. It is anticipated that the TD treatment drugs market will show significant market growth over the forecast period owing to some factors such as increasing prevalence of TD, higher number of unmet needs for treatment of TD and expected launch of pipeline drug.

Although there are various drugs used in treatment of TD, presently only Valbenazine and Deutetrabenazine are approved by the FDA. Other drugs such as benzodiazepines, botulinum toxin, amantadine, dopamine-depleting agents and calcium channel blockers etc. are also used in symptomatic relief from TD.

The report includes in-depth analysis of TD treatment drugs market for period from 2020 to 2029. For the detailed market study, TD treatment drugs market is categorized on the basis of drug types: Valbenazine, Deutetrabenazine and other drugs (benzodiazepines, botulinum toxin, vitamin E, amantadine, levodopa, reserpine, dopamine-depleting agents and calcium channel blockers etc.)

With a view to present in-depth geographical study, the global TD treatment drugs market is segmented on the basis of key regional markets such as North America, Europe, Latin America, Asia Pacific and Middle East and Africa. For country level analysis, TD treatment drugs market is segmented into Canada, United States, United Kingdom, Germany, rest of Europe, Mexico, Brazil, Rest of Latin America, China, Japan, rest of Asia Pacific, GCC and rest of Middle East and Africa.

This report covers detailed study of qualitative information along with statistical data for better understanding of the current market situation and future market scenario. For better understanding about the ongoing market trends and future market prospects, in-depth information about the market drivers, opportunities and challenges of global TD treatment drugs market are covered in report. Attractive investment propositions and company profiling section provide detail information about the key players involved in global TD treatment drugs market.

Based on drug types, the global tardive dyskinesia (TD) treatment drugs market is segmented as follows:

• Valbenazine
• Deutetrabenazine
• Other

For the purpose of this study, the global tardive dyskinesia (TD) treatment drugs market is categorized into:

• North America
• United States
• Canada
• Europe
• U.K.
• Germany
• Rest of Europe
• Asia Pacific
• China
• Japan
• Rest of Asia Pacific
• Latin America
• Brazil
• Mexico
• Rest of Latin America
• Middle East and Africa
• GCC
• Rest of Middle East and Africa

Key Topics Covered:

Chapter 1. Preface

1.1. Report Scope and Description

1.2. Research Methodology

1.2.1. Phase I-Secondary Research

1.2.2. Phase II-Primary Research

1.2.3. Phase III-Expert Panel Review

1.2.4. Assumptions

1.2.5. Approach Adopted

Chapter 2. Executive Summary

2.1. Global Tardive Dyskinesia (TD) Treatment Drugs Market Portraiture

2.1.1. Global Tardive Dyskinesia Treatment Drugs Market, by Drug Type, 2021 (US$ Mn)

2.1.2. Global Tardive Dyskinesia Treatment Drugs Market, by Geography, 2021 (Value %)

Chapter 3. Tardive Dyskinesia (TD) Treatment Drugs: Market Dynamics and Outlook

3.1. Market Definition and Overview

3.2. Drivers

3.3. Challenges

3.4. Opportunities

3.5. Attractive Investment Proposition, by Geography, 2021

3.6. Competitive Landscape

3.6.1. Competitive Landscape, by Key Players, 2021

Chapter 4. Global Tardive Dyskinesia (TD) Treatment Drugs Market, by Drug Type, 2019 - 2029 (US$ Mn)

4.1. Overview

4.2. Valbenazine

4.3. Deutetrabenazine

4.4. Other

Chapter 5. Global Tardive Dyskinesia (TD) Treatment Drugs Market, by Geography, 2019 - 2029

Chapter 6. Company Profiles

Companies Mentioned

• Auspex Pharmaceuticals
• Neurocrine Biosciences Inc.
• Synchroneuron Inc.
• Teva Pharmaceutical Industries Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/46i9nx

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900